SUMMARY
Antimalarial
drugs are used for treatment and prevention of malaria infection, most
antimalarial drugs target and erothrocytic stage of malaria infection which is
the base of infection that causes symptomatic illness. The extent of pre-erythrocytic
(hepatic stage) activity for most antimalarial drugs is not well characterized,
treatment of acute blood stage infection is necessary for malaria caused by all
malaria species, In addition for infection due to plasmodium are ovale or plasmodium
vivax terminal prophylaxis is required with a drug active against hypozoites
(which can remain dormant in the liver for months and occasionally years after
the initial infection) The indication availability are relatively cost for the
drugs, the mechanism of action, resistance and toxicities of antimalarial drugs
and these agents for prevention and
treatment of malaria is discussed in detail, Quinoline Drivative include chloroquine, Amodiaquine, primaguine
and others these drugs have the active against the erythrocytic stage of
infection, primaquine also kill in trahaptic forms and genatoycyte the drug act
by accumulating in the parasite food vacuole and forming a complex with heme
that prevents crystallization in the plasmodium food vacuole, Heme polymerase
activity is inhibited resulting in accumulation of cytotoxic free Heme, 4
amminoquinoline chloroquine-chloroquine was the first drugs produce on a large
scale for treatment and prevention of malaria infection chloroquine has
activity against the blood stages of plasmodium ovale, plasmodium, malariae and
susceptible stains of p vivax and p faliciparium wide spread resistance in most malaria endemic
countries has lead to declare in its use for the treatment of p. falciparum
although it remains effective for treatment of p ovale, p malariae and in most
regions.
INTRODUCTION
Antimalarial
drugs treat or prevent malaria, malaria is parasitic infections due to the
protozoa, plasmodium which is are responsible for malarial a severe disease
that cause abut 225 million cases and 781,000 human death in 2009, despite the
efforts developed during the last decade to fight the disease (Alonso et al.
2011). The internation
al funding allocated to anitmalarial strategies has increased regularly since 2003 for about 0.3 billions of 1.7 billion dollars in 2009 (Collier 2009) allowing many countries to undertakes or strengthen effective fights against the parasite the disease and the vector Nonetheless more than half of the world population still lives in area where there is risk of malaria transmission this drugs kill plasmodium or prevent it growth.
al funding allocated to anitmalarial strategies has increased regularly since 2003 for about 0.3 billions of 1.7 billion dollars in 2009 (Collier 2009) allowing many countries to undertakes or strengthen effective fights against the parasite the disease and the vector Nonetheless more than half of the world population still lives in area where there is risk of malaria transmission this drugs kill plasmodium or prevent it growth.
Chart 1
LIFE CYCLE OF MOSQUITO
Diagram of mosquito life cycle the
mosquito goes through four separated and distinct stages of it life they are
the egg, larva, pupa and adult or image. Each of these stages can be easily
recognized by their special appearance. There are four different mosquitoes
living in the Bay Area, they are Aedes Anopheles, culex and culiseta egg-Eggs
are laid one at a time and the float on the surface of the water. In the case
of culex and culista species their eggs are struck together in rafts, of a
hundred or more eggs while Anopheles and Aedes species lay their eggs separated.
Some lay their eggs in the water while others on damp soil a flooded water,
most egg hatch in larvae within 48 hours
Larva
the larva live in the water and come to the
surface to breathe though spiracles located on the eight abdominal segment they
shed their skin four time growing large after each molting the larva feed on
micro-organism and organic matter in the water in the water on the fourth molt
the larva changes into a pupa pupa the pupa stages is a resting
non-feeding stage, this is the time the mosquito turns into adult it takes
about two days before the adult is fully developed when develop is completely the pupa skin splits
and the mosquito emerges as adult Adult-the newly emerged adult rest on the
surface of the water for a short time to allow it self to dry and all its part
to harden. Also the wings have to spread out and dry properly before it can
fly.
CHART 2
FAMILY OF PARASITE THAT CAUSES MALARIA
The
difficulty in fighting malaria is that five species of plasmodium namely plasmodium-ovale,
plasmodium malariae plasmodium vivax p. faciparum and p. knowsi (until recently
considered as a non human) primate
parasite transmitted by over 30 species of Anopheles female mosquito are known
to cause human malaria the most virulent plasmodium is responsible for severe
clinical malaria and death further more, an increasing prevalence of resistance
of vectors to insecticides are of
parasites to a standard antimalarial drugs has been observed for decades.
CHART THREE
ROUTES BY WHICH THESE PARASITE ENTER
HUMAN BODY
After the bite by an infected Anopheles
the parasite at the sporozoite stage enter the blood and are carried to the
liver where the transverse and invade hapatocytes initiating which is called hepatic or exoerythrocytic phase, During this
asymptomatic periods that last 5-7 days for plasmodium falciparum the sporoziites
developed within the hapatocytes and after several rounds of mitosis produce
several thoughts of new infective forms called the merozoites that the released
into the bloodstream and invade the red blood cello. During this intra
erythrocytic cycle which last 48 hour to plasmodium falciparum and causes the
malaria.
why is it than immunity cannot supers it
The
immune system that enhance immunity to this infection is by the change in human
red blood cell that hinder the malaria parasites ability to invade and
replication within this cells host resistance to malaria therefore it involves not
only blood cell but also genes such as abnormal hemoglobin, glucose -6-
phosphate dylydrogence deficiency and duffty antigen which provide innate
resistance but also gene involves immunity such as the major his to capability
complex response
CHART
FOUR
THE MECHANISM OF RESISTANCE TO
ANTIMALARIAL DRUGS IN PLASMODIUM FALA PARUM.
Plasmodium
drugs resistance to malaria originates from chromosomal mutation analyses using
molecular genetic and bio chemical approaches showed that: (1) Impaired uptake
of chloroquine by the parasite vacuole is a common characteristics of resistant
strains that phenotype correlates with pfmdrl and pfcrt gene mutedmon (2) one
S108N to four (N 511, CS9R, 1164L) point mutation of dihydrofolate reductase, The enzyme target of antifolinics
(pyrimethamine and proguanil gives moderate to high level of resistance to
these drugs. Plasmodium falciparum resistance level may differ according to
place and time depending malaria transmission and drug pressure coupling in vitro
test and using molecular test is essential for the surveillance of replacement
drugs, loco cost biochemistry tools are urgently needed for a prospective
monitoring of resistance.
CHART FIVE
ANTI MALARIA MEDICATION
Some
anti malaria agents are
a. Quinoline Derivative are aminoquinoline chloroquine amodiaquinine 4 methanol quinoline, qulnine
nad quinodine mefloquine, B Aminoquinonline, pimaquine, limefantrine and
humefantrine.
b. Anitifolates Derivation are sulfadoxine, pyimethamine,
Atrovaquine, proquanil, antovaqune, proqunail.
c. Antimicrobial derivative are arterisinine Derivative artemisin in
base combination therapies investigational drugs are tefenoquine pryranaridine.
Chloroquine
Chloroquine is a synthetic 4 aminoquinoline
derivative available as chloroquine was the first drugs produce on a large
scale of treatment and prevent of malaria infection chloroquine has activity
against the blood stages of plasmodium ovale, p, malariae and susceptible
strains of p vivax and p faciparium it is use for their treatment.
![]() |
Pharmacokinetic
Chloroquine
can be given orally by 1.m injection or by slow I.V infusion, it is almost
completely absorbed for GIT. The drugs is distributed widely is extensively
bound to the liver and other body tissues including cornea and R.B.CS it under
goes metabolism in the liver. It is mainly excreted in urine (70% the liver as unchanged
30% as metabolites) Initial half life is 3-4 days but as it is slowly released
from the tissues the terminal half life may be extended to 1-2 month.
Mechanism of action
Chloroquine centers the red blood cells
accumulates in the food vacuoles of the parasite this accumulation may involve
on tapping following protonation specific transport and or binding to a
receptor (e.g. home) the major action of chloroquine is to inhibit the
formation of hemozion (H2) from the heme released by the digestion
of hemozion (Hb) the free heme then lyses membranes and leads to parasite
death. Chloroquine resistance is due to an erythrocyte.
![]() |
Mechanism of action
Decreased
accumulation of chloroquine in the food vacuole two different transporters (CRT
and MDRI) chloroquine resistance transporter and muti drug resistance, have
been implicated. In resistance the functions of these transporters and their
exact roles in chloroquine resistance are not known.
Adverse
effect or toxicity
1. Chloroquine
is usually well tolerated in the dose used for chemoprophylaxis.
2. With
does used to treat the clinical attack of malaria nausea vomiting dizziness
headache urticaria and blurred vision may occur occasionally 3. Larger does
sometime may precipitate retinopathies
Interaction
1. Its
use should avoid in patients with retinal and visual field abnormalities.
2. Ca
2+ and mg 2+ containing antacids decrease its absorption.
3. Chloroquine
is considered safe in pregnancy and in younger children above 2yers of age.
Anitmalarial drug resistance
The
emergence of drug resistance severely limits the arsenal of available drugs
against protozoa pathogen parasite has evolved numerous way of over come the
toxicity of drugs. Mechanism of 1. Resistance mutation in target gene, 2.
Increase production of target decreasing drugs accumulation (including increase
in afflux drug in activation)
Quite of drug resistant involves
mutation in the drugs target so that the drug does not bind or inhibit the
target as well,
Drug resistance can developed quickly in
situation where a single point mutation can confer. Resistance another
mechanism of drug resistance involves expressing higher level of the target
this can be accomplished either through increase transcription and translation
or gene amplification, this level of drug to non toxic product will result in
less drug reaching the target and can also involve the accumulation of mutation
in the same or different target which will have the additive or synergistic
effect parasite with mutation or genetic polymorphisms with confer a decrease
in drugs sensitivity will be selected under drugs pressure.
REFERENCES
Glaxosmithkline major me prescribing Information (2008)
Gasasira A.F; Kamya M.R. J Achan. J et al; High risk of neutropenia In HIV Infection following treatment with artesunate plus amodiagquine for uncomliclated malaria, In Uganda Clin Infect Dis (2008) PP, 46-985.
Deen JL; Von Seldein. L; Dondor P.A. (2008) therapy of uncomplicated malaria In Children. A review of treatment Principles essential drugs and current recommendation Trop med Int Health.
0 comments:
Post a Comment